Upstream / Downstream
Explore pathways related to this product.
Important Ordering DetailsCustom Ordering Details: Product is assembled upon order. Please allow up to three business days for your product to be processed.
the purchase of 3 or more products
To Purchase # 6438S
|6438S||300 µl (3 nmol)||$256.00.0|
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
SignalSilence® CDK8 siRNA I #6438
Western blot analysis of extracts from 293 cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® CDK8 siRNA I (+), using CDK8 (G398) Antibody #4101 and α-Tubulin (11H10) Rabbit mAb #2125. The CDK8 (G398) Antibody confirms silencing of CDK8 expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.Learn more about how we get our images
Gallery: SignalSilence® CDK8 siRNA I #6438
CST recommends transfection with 100 nM SignalSilence® CDK8 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® CDK8 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit CDK8 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
The mammalian Mediator Complex is a multi-subunit protein complex that couples specific transcriptional regulators to RNA polymerase II (Pol II) and the basal transcription machinery. Interactions between distinct Mediator subunits and transcription factors allow for specific gene regulation (reviewed in 1).
Mediator complex interactions control various biological processes, including insulin signaling (2), NF-κB-dependent signaling (3), stem cell pluripotency and self renewal (4,5), and proliferation of colon cancer cells (6,7).
CDK8/Cyclin C, along with Med12 and Med13, constitute a subcomplex within the Mediator Complex thought to act as a molecular switch, inhibiting Pol II recruitment and transcription initiation (8,9). Expression of CDK8 abrogates E2F-1-dependent inhibition of β-catenin activity in colon cancer cells (9). High levels of CDK8 coincide with high β-catenin-dependent transcription in colon cancer cells, and their proliferation can be inhibited by suppressing CDK8 expression (8).
CDK8 can phosphorylate Ser727 on STAT1, which reduces natural killer (NK) cell toxicity (10,11). As such, inhibitors are being pursued as potential therapeutics to enhance NK cell activity and combat a variety of cancer types (12,13).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. SignalSilence is a registered trademark of Cell Signaling Technology, Inc.